LCT Fails to Improve Survival After Dual Immunotherapy in Metastatic NSCLC: LONESTAR Trial
- Local consolidative therapy following dual immunotherapy fails to improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer, according to findings presented on September...
- According to data reported by Mehmet Altan of the MD Anderson Cancer Center in Houston, the median overall survival reached 43.2 months for patients receiving local consolidative therapy...
- The rationale behind local consolidative therapy involves targeting residual or resistant disease sites with radiation or surgery after systemic treatment to delay progression.
Local consolidative therapy following dual immunotherapy fails to improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer, according to findings presented on September 12, 2026, at the World Conference on Lung Cancer in Seoul, South Korea. The phase III LONESTAR trial evaluated whether adding radiation or surgery after an induction regimen of nivolumab and ipilimumab would extend survival compared to immunotherapy alone. Researchers stopped the trial early for futility after enrolling 166 patients with stage IV non-small cell lung cancer who lacked actionable genomic alterations.
Trial Results and Survival Outcomes in the LONESTAR Study
According to data reported by Mehmet Altan of the MD Anderson Cancer Center in Houston, the median overall survival reached 43.2 months for patients receiving local consolidative therapy plus nivolumab and ipilimumab. In comparison, patients treated with nivolumab and ipilimumab alone achieved a median overall survival of 52.8 months, yielding a hazard ratio of 1.14 that was not statistically significant. Progression-free survival followed a similar pattern without significant improvement. MedPage Today reported that median progression-free survival reached 31.3 months in the combination arm versus 24.3 months in the immunotherapy-alone arm. Among the subset of participants diagnosed with oligometastatic disease, median overall survival was 42.0 months with local consolidative therapy compared to 75.8 months for dual immunotherapy alone. Altan stated at a World Conference on Lung Cancer press briefing that while the treatment regimen was feasible, the data do not support using routine local consolidation therapy after ipilimumab and nivolumab induction in metastatic non-small cell lung cancer without actionable genomic alterations outside of a clinical trial.
Context and Subgroup Findings
The rationale behind local consolidative therapy involves targeting residual or resistant disease sites with radiation or surgery after systemic treatment to delay progression. Similar approaches have shown success in other settings, such as the NORTHSTAR trial where adding local consolidative therapy to the targeted drug osimertinib improved progression-free survival in patients with EGFR-mutant advanced disease. For the LONESTAR study, eligible participants possessed wild-type EGFR and ALK status and had not previously received immunotherapy. Following 12 weeks of induction therapy with nivolumab and ipilimumab, participants without disease progression or severe toxicity were randomized to continue dual immunotherapy alone or undergo local consolidative therapy alongside it. Of those assigned to local consolidation, 71 patients received radiation to at least one site and 16 underwent surgery. Subgroup analysis identified a potential survival benefit for younger participants under the age of 65 who received the combination strategy. However, post-hoc analysis also revealed an association between mediastinal radiation and increased lymphopenia within the local consolidative therapy arm.